ReviewCancer imaging : the official publication of the International Cancer Imaging Society2024
Clinical scoring systems, molecular subtypes and baseline [
Review in Cancer imaging : the official publication of the International Cancer Imaging Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.European journal of nuclear medicine and molecular imaging · 2026Article
- Individualized metabolic brain network alterations in diffuse large B-cell lymphoma: anBMC medical imaging · 2026Article
- Distinguishing lymphoma from benign lymphadenopathy in fever of unknown origin using a diagnostic model based on PET/CT and clinical-laboratory parameters.EJNMMI research · 2026Article
- Article
- Metabolic tumor volume and total lesion glycolysis for predicting prognosis in diffuse large B-cell lymphoma: a retrospective PET/CT study.Frontiers in oncology · 2026Article
- Characteristics of pulmonary lymphoma on baselineQuantitative imaging in medicine and surgery · 2025Article
- Research hotspots and trends of artificial intelligence in lymphoma: A bibliometric analysis from 2010 to 2024.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous hematological malignancy resulting in a range of outcomes, and the early prediction of these outcomes has important implications for patient management. Clinical scoring systems provide the most commonly used prognostic evaluation criteria, and the value of genetic testing has also been confirmed by in-depth research on molecular typing. [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.